[go: up one dir, main page]

WO2025083071A3 - Conjugués anticorps-médicament - Google Patents

Conjugués anticorps-médicament Download PDF

Info

Publication number
WO2025083071A3
WO2025083071A3 PCT/EP2024/079226 EP2024079226W WO2025083071A3 WO 2025083071 A3 WO2025083071 A3 WO 2025083071A3 EP 2024079226 W EP2024079226 W EP 2024079226W WO 2025083071 A3 WO2025083071 A3 WO 2025083071A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
moiety
drug conjugates
antigen
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/079226
Other languages
English (en)
Other versions
WO2025083071A2 (fr
Inventor
Dipti THAKKAR
Bhushan DHARMADHIKARI
Shalini PALIWAL
Benjamin AYERS
Rajavel Srinivasan
Lisa OOI
Kevin Fongching CHAU
Roberto Tirado MAGALLANES
Debleena RAY
Jerome Douglas BOYD-KIRKUP
Piers INGRAM
Gary KHOO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hummingbird Bioscience Holdings Ltd
Original Assignee
Hummingbird Bioscience Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hummingbird Bioscience Holdings Ltd filed Critical Hummingbird Bioscience Holdings Ltd
Publication of WO2025083071A2 publication Critical patent/WO2025083071A2/fr
Publication of WO2025083071A3 publication Critical patent/WO2025083071A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une molécule de liaison à l'antigène qui se lie à un antigène cible, comprenant (i) un fragment de liaison à l'antigène cible, et (ii) au moins un fragment lieur-charge utile, la molécule de liaison à l'antigène comprenant (a) un fragment inhibiteur de réponse à l'endommagement de l'ADN (DDR), et (b) un fragment inhibiteur d'ADN topoisomérase 1 (TOP1).
PCT/EP2024/079226 2023-10-16 2024-10-16 Conjugués anticorps-médicament Pending WO2025083071A2 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202363590558P 2023-10-16 2023-10-16
US202363590533P 2023-10-16 2023-10-16
US63/590,558 2023-10-16
US63/590,533 2023-10-16
US202463549667P 2024-02-05 2024-02-05
US63/549,667 2024-02-05
US202463556573P 2024-02-22 2024-02-22
US63/556,573 2024-02-22
US202463645239P 2024-05-10 2024-05-10
US63/645,239 2024-05-10
US202463694528P 2024-09-13 2024-09-13
US63/694,528 2024-09-13

Publications (2)

Publication Number Publication Date
WO2025083071A2 WO2025083071A2 (fr) 2025-04-24
WO2025083071A3 true WO2025083071A3 (fr) 2025-06-19

Family

ID=93214039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/079226 Pending WO2025083071A2 (fr) 2023-10-16 2024-10-16 Conjugués anticorps-médicament

Country Status (1)

Country Link
WO (1) WO2025083071A2 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018237335A1 (fr) * 2017-06-23 2018-12-27 VelosBio Inc. Immunoconjugués d'anticorps ror1
WO2019008164A1 (fr) * 2017-07-06 2019-01-10 Centre National De La Recherche Scientifique Bioconjugués présentant un degré de conjugaison régulé, leur procédé de préparation et réactifs pour leur préparation
WO2021260579A1 (fr) * 2020-06-24 2021-12-30 Astrazeneca Uk Limited Association d'un conjugué anticorps-médicament et d'un inhibiteur d'atr
WO2022175595A1 (fr) * 2021-02-16 2022-08-25 Glykos Finland Oy Charges utiles de lieurs et leurs conjugués
WO2022187370A1 (fr) * 2021-03-03 2022-09-09 R.P. Scherer Technologies, Llc Lieurs ramifiés pour conjugués anticorps-médicament et leurs méthodes d'utilisation
WO2022199429A1 (fr) * 2021-03-22 2022-09-29 成都科岭源医药技术有限公司 Procédé de préparation d'un lieur d'adc à double médicament et son utilisation
WO2023125806A1 (fr) * 2021-12-30 2023-07-06 苏州爱科百发生物医药技术有限公司 Conjugué pour la prévention et le traitement d'infections virales et son utilisation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018237335A1 (fr) * 2017-06-23 2018-12-27 VelosBio Inc. Immunoconjugués d'anticorps ror1
WO2019008164A1 (fr) * 2017-07-06 2019-01-10 Centre National De La Recherche Scientifique Bioconjugués présentant un degré de conjugaison régulé, leur procédé de préparation et réactifs pour leur préparation
WO2021260579A1 (fr) * 2020-06-24 2021-12-30 Astrazeneca Uk Limited Association d'un conjugué anticorps-médicament et d'un inhibiteur d'atr
WO2022175595A1 (fr) * 2021-02-16 2022-08-25 Glykos Finland Oy Charges utiles de lieurs et leurs conjugués
WO2022187370A1 (fr) * 2021-03-03 2022-09-09 R.P. Scherer Technologies, Llc Lieurs ramifiés pour conjugués anticorps-médicament et leurs méthodes d'utilisation
WO2022199429A1 (fr) * 2021-03-22 2022-09-29 成都科岭源医药技术有限公司 Procédé de préparation d'un lieur d'adc à double médicament et son utilisation
WO2023125806A1 (fr) * 2021-12-30 2023-07-06 苏州爱科百发生物医药技术有限公司 Conjugué pour la prévention et le traitement d'infections virales et son utilisation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
FONTAINE SHAUN D. ET AL: "A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors", vol. 3, no. 5, 24 May 2023 (2023-05-24), pages 908 - 916, XP093069462, ISSN: 2767-9764, Retrieved from the Internet <URL:https://aacrjournals.org/cancerrescommun/article-pdf/3/5/908/3333717/crc-22-0517.pdf> DOI: 10.1158/2767-9764.CRC-22-0517 *
MCKERTISH CANDICE MARIA ET AL: "A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer", vol. 15, no. 8, 26 July 2023 (2023-07-26), Switzerland, pages 2020, XP093236584, ISSN: 1999-4923, Retrieved from the Internet <URL:https://www.mdpi.com/1999-4923/15/8/2020/pdf> DOI: 10.3390/pharmaceutics15082020 *
POMMIER YVES ET AL: "New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads", vol. 29, no. 6, 14 March 2023 (2023-03-14), US, pages 991 - 993, XP093237593, ISSN: 1078-0432, Retrieved from the Internet <URL:https://aacrjournals.org/clincancerres/article-pdf/29/6/991/3281380/991.pdf> DOI: 10.1158/1078-0432.CCR-22-3640 *
QI LI: "A new wave of innovations within the DNA damage response", vol. 8, no. 1, 8 September 2023 (2023-09-08), XP093167112, ISSN: 2059-3635, Retrieved from the Internet <URL:https://www.nature.com/articles/s41392-023-01548-8> DOI: 10.1038/s41392-023-01548-8 *
SCHLAM ILANA ET AL: "Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 190, 9 August 2023 (2023-08-09), XP087397882, ISSN: 1040-8428, [retrieved on 20230809], DOI: 10.1016/J.CRITREVONC.2023.104090 *
TALUKDAR ARINDAM ET AL: "Topoisomerase I inhibitors: Challenges, progress and the road ahead", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER MASSON, AMSTERDAM, NL, vol. 236, 2 April 2022 (2022-04-02), XP087049272, ISSN: 0223-5234, [retrieved on 20220402], DOI: 10.1016/J.EJMECH.2022.114304 *
THOMAS ANISH ET AL: "Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress", CANCER CELL, CELL PRESS, US, vol. 39, no. 4, 12 April 2021 (2021-04-12), pages 566, XP086534029, ISSN: 1535-6108, [retrieved on 20210412], DOI: 10.1016/J.CCELL.2021.02.014 *
YAMAZAKI CHISATO M. ET AL: "Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance", vol. 12, no. 1, 1 December 2021 (2021-12-01), XP055940303, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-021-23793-7.pdf> DOI: 10.1038/s41467-021-23793-7 *

Also Published As

Publication number Publication date
WO2025083071A2 (fr) 2025-04-24

Similar Documents

Publication Publication Date Title
DK0679094T3 (da) Forbindelser til målretning
NL300903I2 (nl) Inotuzumab ozogamicin
GEP20257822B (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP4570319A3 (fr) Composés ciblant la brm et procédés d&#39;utilisation associés
WO2007112193A3 (fr) Conjugués de groupements se liant à la camptothécine
WO2008088658A3 (fr) Supports polymères d&#39;agents thérapeutiques et fractions de reconnaissance pour un ciblage à base d&#39;anticorps de sites de maladie
WO2023236949A8 (fr) Conjugué anticorps-médicament anti-b7h3 et son utilisation
WO2002009754A1 (fr) Nouveaux remedes contre le cancer
WO2019218944A3 (fr) Anticorps ciblant l&#39;axl, conjugué anticorps-médicament, son procédé de préparation, et utilisation associée
AU2002308628A1 (en) Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
WO2025083071A3 (fr) Conjugués anticorps-médicament
WO2005079423A3 (fr) Immunite programmable chimiquement
WO2024138128A3 (fr) Conjugués d&#39;agent de dégradation de céréblon et leurs utilisations
WO2023220620A3 (fr) Conjugués anticorps-médicament 5t4 et leurs utilisations
WO2023205659A3 (fr) Anticorps glyco-modifiés
WO2007027796A3 (fr) Essai de ligature de proximite avec des conjugues peptidiques &#39;burrs&#39; et des aptameres permettant une detection sensible de spores et de cellules cancereuses
WO2024211236A3 (fr) Conjugués anticorps-médicament et leurs utilisations
WO2024249946A3 (fr) Procédés de fabrication de systèmes de résidence gastrique
WO2007079404A3 (fr) Conjugues medicament-polymere
WO2024163530A3 (fr) Nouveaux anticorps anti-ccr4 et produits dérivés
WO2023147588A3 (fr) Fusions nanocorps-cytokine anti-ecm à affinité améliorée et leurs applications
WO2021234592A3 (fr) Conjugaison spécifique à un site d&#39;anticorps monoclonaux glycosylés avec la transglutaminase
WO2024206573A3 (fr) Conjugués anticorps-médicament amhrii et leurs utilisations
GB2289679A (en) Compounds for targeting
WO2024197140A3 (fr) Conjugués anticorps-médicament dll3 et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24794033

Country of ref document: EP

Kind code of ref document: A2